Surgical Science Sweden AB Cash Flow-to-Debt Ratio
Surgical Science Sweden AB cash flow-to-debt ratio. Surgical Science Sweden AB (SUS) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2026, meaning its operating cash flow of Skr15.31 Million could theoretically repay 0% of its total liabilities (Skr420.02 Million) in one year. Check SUS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Surgical Science Sweden AB (2015–2025)
Cash flow-to-debt ratio of Surgical Science Sweden AB from 2015 to 2025. Historical debt coverage capacity for Surgical Science Sweden AB across 11 annual periods. Check Surgical Science Sweden AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Surgical Science Sweden AB Cash Flow-to-Debt Ratio by Year (2015–2025)
Surgical Science Sweden AB cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Surgical Science Sweden AB. For the full cash flow conversion analysis, see Surgical Science Sweden AB cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | Skr79.80 Million | Skr418.31 Million | ▼ -9.5% |
| 2024 | 0.21x | Skr137.22 Million | Skr651.03 Million | ▼ -68.4% |
| 2023 | 0.67x | Skr238.29 Million | Skr357.46 Million | ▲ +112.7% |
| 2022 | 0.31x | Skr129.49 Million | Skr413.11 Million | ▲ +215.2% |
| 2021 | 0.10x | Skr39.08 Million | Skr393.06 Million | ▼ -80.6% |
| 2020 | 0.51x | Skr23.23 Million | Skr45.22 Million | ▼ -49.3% |
| 2019 | 1.01x | Skr55.20 Million | Skr54.54 Million | ▲ +198.4% |
| 2018 | 0.34x | Skr6.88 Million | Skr20.28 Million | ▼ -42.7% |
| 2017 | 0.59x | Skr7.94 Million | Skr13.40 Million | ▲ +82.6% |
| 2016 | 0.32x | Skr13.40 Million | Skr41.30 Million | ▲ +51.8% |
| 2015 | 0.21x | Skr7.50 Million | Skr35.10 Million | — |